Drug Guidance for Subsidy 16/09/2025 Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended datopotamab deruxtecan ... See all × 16/09/2025 Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended datopotamab deruxtecan (Dato-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The decision was based on the unfavourable clinical and cost effectiveness of Dato-DXd compared with chemotherapy, at the price proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for datopotamab deruxtecan are provided in the Annex.
INTRAVENOUS Select a brand starting with the letter: D DATROWAY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL [SIN17234P]